Inhibrx Biosciences (INBX) investor relations material

Mission and financial highlights

• Focus on discovering and developing biologic treatments for life-threatening conditions.

• $153.1M in cash and cash equivalents as of 9/30/2025.

• Over 300 patients treated with ozekibart (INBRX-109) and over 175 with INBRX-106.

• 14.5M common shares outstanding, 19.6M fully diluted.

• In-house expertise spans discovery, protein engineering, clinical development, and commercialization.

Strategic focus and milestones

• High internal ownership aligns interests with investors; 2026 milestones expected to drive value.

• Ozekibart transaction paused pending INBRX-106 Phase 2 Hexagon trial results.

• Ozekibart BLA submission for metastatic or unresectable chondrosarcoma expected in 1H 2026.

• Key data readouts for INBRX-106 in HNSCC and CRC anticipated in 2H 2026.

• Potential FDA meeting for accelerated approval in Ewing sarcoma and/or fourth line CRC.

INBRX-106: Next-generation OX40 agonist

• Designed to boost PD-1 efficacy via hexavalent OX40 agonism, enhancing T-cell activation.

• Outperforms bivalent OX40 agonists by enabling high-order OX40 clustering and stronger signaling.

• Demonstrates robust, dose-dependent expansion of CD4+ and CD8+ memory T cells.

• Phase 1 data show tumor reduction or stabilization in heavily pretreated NSCLC and HNSCC patients.

• Randomized Phase 2/3 Hexagon HN study in 1L HNSCC to validate clinical benefit in combination with pembrolizumab.